Protecting Device Innovation: An Interview With Tom Fogarty

Noted physician-entrepreneur Tom Fogarty has long been known for inventing breakthrough products. Here he discusses his recent efforts to protect the medical device innovation model, and corrects what he sees as serious flaws in its long-term viability, especially in the U.S.

It’s hard to imagine Thomas J. Fogarty, MD, wearing still another hat and playing yet a different role in the medical device industry. You would think that by now, having spent nearly 50 years in the business, he has pretty much done it all – surgeon, inventor, entrepreneur, investor, and mentor ( and certainly earned the right to relax and enjoy his winery in the Santa Cruz Mountains. But even with all that Tom Fogarty has accomplished – he was recently named the first Fellow of the National Academy of Inventors ( that assumption sells him short. His new mission is focused on protecting the innovation ecosystem that has produced the device technology revolution that he has helped lead.

Fogarty’s efforts have resulted in more than 100 inventions. He has more than 70 patents to his credit and has...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By 

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.

Philips Deals Itself A Strong Hand In POCUS Stakes

 
• By 

Point of care ultrasound technology that can be used by non-sonographers will plug gaps in workforce coverage and bring new critical care capabilities to the frontline of care, said Royal Philips.

Liquid Biopsy Startup Mursla Bio Launches AI Precision Medicine Platform

 

The new AI Precision Medicine platform supports the company’s flagship product, EvoLiver, which received US FDA breakthrough device designation in April.